Praxis epilepsy drug approval filing is planned for early 2025 after collaborative discussions with the FDA. Rezolute shares fell, Centessa named a new CEO.
Author: PharmaSignal News Desk
AC Immune Parkinson’s drug shows positive data, prompting regulatory feedback request. Shares rise by double-digits.
Apple Tree Ventures files for bankruptcy amid a funding dispute with billionaire backer, affecting its startups and restructuring plans.
Lilly retatrutide obesity drug demonstrates up to 29% weight loss in Phase 3 study, setting a new benchmark for competitors.
ACA subsidy alternative proposed by Crapo and Cassidy aims to enhance health savings accounts for bronze or catastrophic plans.
Prolynx obesity drugs aim to use novel linker technology for monthly or quarterly administration, backed by a $70M Series A funding.
FDA Approves Augmentin XR, marking the first drug in the National Priority Voucher program, enhancing antibiotic availability in the US.
PsiThera, formerly Psivant Therapeutics, raises $47M for AI-designed oral drugs targeting immune conditions.
Novartis Ianalumab Success marks a significant achievement in treating immune thrombocytopenia, impacting low platelet counts.
Pfizer obesity pill China deal involves a $2 billion agreement with Fosun Pharma, aiming to enhance its weight loss medication offerings.